| Autor: |
Sánchez-Valle J; Life Sciences Department, Barcelona Supercomputing Center, Barcelona, 08034, Spain., Correia RB; Instituto Gulbenkian de Ciência, Street, Oeiras, 2780-156, Portugal., Camacho-Artacho M; Life Sciences Department, Barcelona Supercomputing Center, Barcelona, 08034, Spain.; Instituto Gulbenkian de Ciência, Street, Oeiras, 2780-156, Portugal.; Department of Biomedicine, asel University Hospital and University of Basel, Basel, CH-4031, Switzerland.; Universidade Regional de Blumenau, Blumenau, 89030-903, Brazil.; Department of Systems Science and Industrial Engineering, Binghamton University, Binghamton, 13902, USA.; ICREA, Barcelona, 08010, Spain., Lepore R; Life Sciences Department, Barcelona Supercomputing Center, Barcelona, 08034, Spain.; Department of Biomedicine, asel University Hospital and University of Basel, Basel, CH-4031, Switzerland., Mattos MM; Universidade Regional de Blumenau, Blumenau, 89030-903, Brazil., Rocha LM; Instituto Gulbenkian de Ciência, Street, Oeiras, 2780-156, Portugal.; Department of Systems Science and Industrial Engineering, Binghamton University, Binghamton, 13902, USA., Valencia A; Life Sciences Department, Barcelona Supercomputing Center, Barcelona, 08034, Spain.; ICREA, Barcelona, 08010, Spain. |
| Abstrakt: |
The co-administration of drugs known to interact has a high impact on morbidity, mortality, and health economics. We study the drug-drug interaction (DDI) phenomenon by analyzing drug administrations from population-wide Electronic Health Records (EHR) in Blumenau (Brazil), Catalonia (Spain), and Indianapolis (USA). Despite very different health care systems and drug availability, we find a common large risk of DDI administration that affected 13 to 20% of patients in these populations. In addition, the increasing risk of DDI as patients age is very similar across all three populations but is not explained solely by higher co-administration rates in the elderly. We also find that women are at higher risk of DDI overall- except for men over 50 years old in Indianapolis. Finally, we show that PPI alternatives to Omeprazole can reduce the number of patients affected by known DDIs by up to 21% in both Blumenau and Catalonia, and 2% in Indianapolis, exemplifying how analysis of EHR data can lead to a significant reduction of DDI and its associated human and economic costs. Although the risk of DDIs increases with age, administration patterns point to a complex phenomenon that cannot be solely explained by polypharmacy and multimorbidity. The lack of safer drug alternatives, particularly for chronic conditions, further overburdens health systems, thus highlighting the need for disruptive drug research. |
